Biotechnology

A new blood test for Alzheimer's from Spear Bio wins a top tech award. Its unprecedented sensitivity could revolutionize early detection and treatment.

Orchestra Life Sciences' meteoric rise on the Inc. 5000 is more than a growth story; it's a signal of the industrialization of advanced therapies.

With a strong cash position and key clinical trials advancing for ALS and FTD, Coya is executing a disciplined strategy to tackle neurodegenerative diseases.

The biotech has gone all-in on its lead drug, bel-sar, cutting 20% of staff and shelving a promising bladder cancer program to secure its financial future.

With the appointment of Dr. Jeffrey Sherman, Kalohexis signals a major push to conquer the challenging metabolic disease market with its novel pipeline.

With 92% response rates in a deadly cancer and $1B in the bank, Tango Therapeutics is not just developing a drug—it's building a new industrial model for precision oncology.

With promising data for its lead cancer drug and a fortified financial runway, C4 Therapeutics is executing a tangible plan to fight a relentless disease.

With a massive Series B and the launch of a Phase 3 study, Vaderis Therapeutics is poised to deliver the first-ever approved therapy for a long-neglected rare disease.

With a strong cash runway, Nkarta pushes its off-the-shelf NK cell therapy into community clinics, setting the stage for a pivotal data reveal in 2026.

With promising early data and a robust balance sheet, Palisade Bio is advancing its targeted IBD therapy, PALI-2108, into crucial Phase 2 trials.

With major clinical trials progressing and a $110M war chest, Orchestra BioMed is orchestrating a potential shift in cardiovascular treatment.

New 48-week data for envudeucitinib shows 54% of patients achieved complete skin clearance, setting a new bar for oral therapies and positioning Alumis for market disruption.

Metagenomi Therapeutics is on track for a pivotal 2027 clinical trial, but its advanced gene editing tech faces a market wary of high-cost cures.

Strong Attruby sales and new data showing superiority fuel BridgeBio’s momentum as it prepares for three FDA decisions, backed by a new $1B financing.

Bristol Myers Squibb's massive Texas campus isn't just about jobs. It's a high-tech play to reshore drug manufacturing and revolutionize how we make medicine.

In a strategic move, Xcellon acquires a GMP facility, aiming to become a key CRDMO for complex biologics and bolster America's biotech supply chain.

Former World Bank President Dr. Jim Yong Kim joins ImmunityBio. Is this a new model for biotech social impact or a high-stakes bet on global expansion?

Heron Therapeutics withdraws guidance after a patent blow to its top drug, forcing a strategic review. Can strong growth in new acute care products save it?

Revenue missed and its stock plunged, but Quanterix is betting on a new C-suite and its Alzheimer's test to navigate market headwinds and deliver on its promise.

The biotech pioneering cellular rejuvenation just added the finance chief behind Spark's $4.3B sale to its board. It’s a clear sign the firm is preparing to scale.